In the first part of this webinar, Dan Georgess, PhD, Director of Alliance Management at TransCure bioServices, will present an overview of the advantages of using humanized mouse models in immuno-oncology preclinical studies. Humanized mouse models offer several advantages, including the ability to study cancer therapies in vivo, decipher different types of mechanisms of action such as immune checkpoint inhibitors, ADCC, T cell engagers, and cell therapies. Dr. Georgess will also present several case studies demonstrating the advantages of using humanized mouse models for drug trials in immuno-oncology.
In the second part of the webinar, Eleonora Leucci, PhD, Professor at The Laboratory for RNA Cancer Biology, will explore a novel RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to immune checkpoint blockade. The strategy involves using humanized mouse models transplanted with melanoma PDX to study a novel lncRNA LISR-based therapeutic strategy. The study identifies an RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to ICB by downregulating LISR, which leads to strong anti-tumor immune responses in melanoma in vitro, ex vivo, and in vivo, and re-sensitizes to immune checkpoint blockade. Mechanistically, LISR contributes to melanoma immunogenicity by affecting the translation of the checkpoint inhibitor PDL-1 and the assembly of the glycocalyx.
Fill out the form to gain immediate access to this presentation.